Brokers Set Expectations for EYPT Q1 Earnings

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Investment analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of EyePoint Pharmaceuticals in a note issued to investors on Thursday, May 15th. HC Wainwright analyst Y. Chen expects that the company will earn ($0.74) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $22.00 target price on the stock. The consensus estimate for EyePoint Pharmaceuticals' current full-year earnings is ($2.13) per share. HC Wainwright also issued estimates for EyePoint Pharmaceuticals' Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.74) EPS, Q4 2026 earnings at ($0.67) EPS and FY2026 earnings at ($2.90) EPS.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.65). The firm had revenue of $24.50 million for the quarter, compared to analyst estimates of $8.84 million. EyePoint Pharmaceuticals had a negative return on equity of 43.01% and a negative net margin of 226.57%.

A number of other analysts have also issued reports on EYPT. Chardan Capital lowered their target price on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. Wall Street Zen raised EyePoint Pharmaceuticals to a "sell" rating in a report on Friday, March 14th. Finally, Mizuho reduced their price objective on EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research report on Friday, May 16th. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating to the company. According to data from MarketBeat, EyePoint Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $25.38.

EyePoint Pharmaceuticals Trading Up 1.4%

EYPT traded up $0.08 during midday trading on Monday, reaching $5.68. The company's stock had a trading volume of 368,862 shares, compared to its average volume of 815,934. The stock has a market cap of $390.85 million, a P/E ratio of -2.84 and a beta of 1.58. The company has a fifty day simple moving average of $5.82 and a 200 day simple moving average of $7.12. EyePoint Pharmaceuticals has a twelve month low of $3.91 and a twelve month high of $13.99.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd grew its holdings in shares of EyePoint Pharmaceuticals by 127.8% in the 1st quarter. Dynamic Technology Lab Private Ltd now owns 73,310 shares of the company's stock worth $397,000 after purchasing an additional 41,132 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its holdings in shares of EyePoint Pharmaceuticals by 7.8% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 6,200,000 shares of the company's stock worth $33,604,000 after purchasing an additional 450,000 shares during the last quarter. MYDA Advisors LLC grew its holdings in shares of EyePoint Pharmaceuticals by 12.5% in the 1st quarter. MYDA Advisors LLC now owns 180,000 shares of the company's stock worth $976,000 after purchasing an additional 20,000 shares during the last quarter. Walleye Capital LLC bought a new stake in shares of EyePoint Pharmaceuticals in the 1st quarter worth about $180,000. Finally, EntryPoint Capital LLC bought a new stake in shares of EyePoint Pharmaceuticals in the 1st quarter worth about $186,000. 99.41% of the stock is owned by institutional investors.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.